Sclerostin is certainly involved in the onset of osteoporosis because the administration of anti-sclerostin antibodies (Romosozumab) increased bone formation and decreased bone resorption, which, in turn, markedly increased bone mass in osteoporosis models and patients as previously reported [80,81,82,83,84]. The gene discussed is SOST; the disease is osteoporosis.